Skip to main content

NCI at ASH 2020 Virtual Meeting

The National Cancer Institute (NCI) will be participating in the American Society of Hematology Virtual Annual Meeting, December 5-8, 2020.

NCI experts are taking part in several oral presentations and poster sessions throughout the meeting, as shown below. In addition, you can visit NCI in the virtual exhibit hall during the conference.

Registration for the ASH Virtual Meeting is available at varying rates and options for accessing on-demand content following the event. Register now.

Oral Presentations Featuring NCI Staff

All sessions shown in Pacific Time

Abstract NCI Participant(s) Date and Time

Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain

  • Lekha Mikkilineni, MD
  • Danielle Vanasse, BS
  • Jennifer N. Brudno, MD
  • Jennifer Mann, CRNP
  • Richard Sherry, MD
  • Stephanie L Goff, MD 
  • James C Yang, MD
  • Norris Lam, BS
  • Maryalice Stetler-Stevenson, MD, PhD

Sunday, December 6

2:15 PM

Chromosomal Aberrations in Pre-HCT Blood Samples and Outcomes after Transplantation in Patients with Myelofibrosis
 

  • Youjin Wang, PhD
  • Derek W Brown, PhD
  • Weiyin Zhou, MS 
  • Meredith Yeager, PhD 
  • Stephen J. Chanock, MD
  • Mitchell Machiela, PhD
  • Shahinaz Gadalla, MD, PhD

Monday, December 7

7:30 AM

Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
 

  • Christopher Melani, MD
  • Rahul Lakhotia, MD
  • Stefania Pittaluga, MD, PhD
  • Milos D. Miljkovic, MD, MSc
  • James D. Phelan, PhD
  • Jagan R. Muppidi, MD, PhD
  • Anna Marie Juanitez, RN
  • Seth M. Steinberg, PhD
  • Mark Roschewski, MD
  • Louis M. Staudt, MD, PhD
  • Wyndham H. Wilson, MD, PhD 

Monday, December 7

9:15 AM

Poster Sessions Featuring NCI Staff

All sessions shown in Pacific Time

In addition to the oral sessions noted above, NCI experts are included in a number of poster sessions:

Abstract Date and Time

Disease Progression and Outcomes in Patients with Telomere Biology Disorders

Saturday, December 5

7:00 AM-3:30 PM

Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study
 

Saturday, December 5

7:00 AM-3:30 PM

Allogeneic Hematopoietic Stem-Cell Transplantation in Patients with GATA 2 Deficiency: Influence of Donor Stem Cell Source and Post-Transplantation Cyclophosphamide

Sunday, December 6

7:00 AM-3:30 PM

Chromosomal Aberrations in Pre-HCT Blood Samples and Outcomes after Transplantation in Patients with Myelofibrosis

Sunday, December 6

7:00 AM-3:30 PM

Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma

Sunday, December 6

7:00 AM-3:30 PM

Rebound and Overshoot of Donor Specific Antibodies to HLA Following Plasma Exchanges during Hematopoietic Progenitor Cell Transplantation: A Case Report

Sunday, December 6

7:00 AM-3:30 PM

Pre-Transplant Clonal Mosaicism Is Associated with Increased Relapse and Lower Survival in Acute Lymphoblastic Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplant 

Monday, December 7

7:00 AM-3:30 PM

Genotype-Phenotype Associations in Patients with Fanconi Anemia: National Cancer Institute Cohort

Monday, December 7

7:00 AM-3:30 PM

Phase 1 Study of Alvelestat, an Oral Neutrophil Elastase Inhibitor, in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation

Monday, December 7

7:00 AM-3:30 PM

Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Monday, December 7

7:00 AM-3:30 PM

Pre-Transplant Clonal Mosaicism Is Associated with Increased Relapse and Lower Survival in Acute Lymphoblastic Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplant

Monday, December 7

7:00 AM-3:30 PM

  • Posted:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “NCI at ASH 2020 Virtual Meeting was originally published by the National Cancer Institute.”